Trial Profile
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- 13 Sep 2023 Primary endpoint (FEV1 rate decline) has not been met according to results presented at the 33rd Annual Congress of the European Respiratory Society.
- 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society
- 26 Sep 2022 Status changed from recruiting to completed.